Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tumor Markers in Breast Cancer. Tumormarker beim Mammakarzinom

Tumor Markers in Breast Cancer. Tumormarker beim Mammakarzinom Onkologie reast cancer remains ihe most common malignancy affecting women with still increasing incidence. The lifetime risk of developing this malignancy is 12.2%, the lifetime risk of death is 3.6%. Multiple factors are known to be associated with an increase in breast cancer risk. These include genetic and familial factors, hormonal factors (early mcnarche, late menopause and late first pregnancy), diet, environmental factors and benign breast diseases. The decrease of mortality since years in the United States and United Kingdom f 1} and the almost stable mortality in Germany [2] and other European countries may be the result of improved outcome secondary to earlier detection and advances in treatment. Due to mammography screening programs and public awareness, breast cancer is nowadays diagnosed at an earlier stage and more patients are present with node-negative disease. The treatment of primary breast cancer usually includes surgery and/or radiotherapy.'Following surgery, there is increasing use of adjuvant therapies (e.g., tamoxifen or chemotherapy). In the past decade, several trials using systemic treatment after primary surgery showed a significant improvement in survival for treated patients as compared to controls. In order to rationally administer systemic therapy to patients with local disease, it is necessary to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Laboratoriums Medizin / Journal of Laboratory Medicine de Gruyter

Tumor Markers in Breast Cancer. Tumormarker beim Mammakarzinom

Download PDF
10 pages

Loading next page...
 
/lp/de-gruyter/tumor-markers-in-breast-cancer-tumormarker-beim-mammakarzinom-HQQ9iiskEP

References (48)

Publisher
de Gruyter
Copyright
Copyright © 2009 Walter de Gruyter
ISSN
0342-3026
eISSN
1439-0477
DOI
10.1515/labm.2001.25.9-10.343
Publisher site
See Article on Publisher Site

Abstract

Onkologie reast cancer remains ihe most common malignancy affecting women with still increasing incidence. The lifetime risk of developing this malignancy is 12.2%, the lifetime risk of death is 3.6%. Multiple factors are known to be associated with an increase in breast cancer risk. These include genetic and familial factors, hormonal factors (early mcnarche, late menopause and late first pregnancy), diet, environmental factors and benign breast diseases. The decrease of mortality since years in the United States and United Kingdom f 1} and the almost stable mortality in Germany [2] and other European countries may be the result of improved outcome secondary to earlier detection and advances in treatment. Due to mammography screening programs and public awareness, breast cancer is nowadays diagnosed at an earlier stage and more patients are present with node-negative disease. The treatment of primary breast cancer usually includes surgery and/or radiotherapy.'Following surgery, there is increasing use of adjuvant therapies (e.g., tamoxifen or chemotherapy). In the past decade, several trials using systemic treatment after primary surgery showed a significant improvement in survival for treated patients as compared to controls. In order to rationally administer systemic therapy to patients with local disease, it is necessary to

Journal

Laboratoriums Medizin / Journal of Laboratory Medicine – de Gruyter

Published: Jan 1, 2001

There are no references for this article.